Burgdorf - The guidance of CHF 60 million EBIT for the 2017/18 financial year announced in November 2017 remains unchanged. Ypsomed is investing in its global expansion and the establishment of new subsidiaries for the insulin pump business. Ypsomed expects sustained growth in the Ypsomed Delivery Systems (YDS) segmen.
Due to the very positive feedback from the markets regarding the in-house insulin pump mylife™ YpsoPump®, Ypsomed is consistently investing in the global expansion and the establishment of new subsidiaries, currently in Australia, Spain and most recently Canada. The window of opportunity for expansion is very favourable, as the gap from withdrawal of competitors from the insulin pump market can be filled by Ypsomed.
Business in the YDS segment continues to grow strongly and sustainably. The project business for YDS continues to be subject to industry-specific uncertainties. As already communicated, many factors such as the duration of clinical trials and market registrations are not in Ypsomed's hands. As a result, there may be delays in project commercialisation. Due to the large number of customer projects, the YDS pipeline is still well-filled.
For the next financial year 2018/19, Ypsomed continues to expect an increased operating profit. An important component of this is the payment of approximately CHF 50 million to be made by Insulet Corp. As already announced at the media and analysts' conference in November 2017, Ypsomed expects a temporary decline in profits in the following financial year 2019/20, followed by a clear and long-term increase in profitability.
Ypsomed will publish more detailed information and a range of outlook figures with the publication of the financial year 2017/18 figures at the end of May.